The Iran Hemophilia Society has officially announced the reopening of the case concerning HIV-positive blood products, emphasizing its intention to file a lawsuit against the implicated French company.
In a press conference held on Tuesday, Nazanin Farzadifar, the Chief Executive Officer of the Iran Hemophilia Society, stated that the reopening of the case is the culmination of a year’s worth of relentless efforts by the Iran Hemophilia Society, the High Council for Human Rights, the Prosecutor General’s Office, and other institutions.
“This is the first time in 40 years that we have reopened the contaminated blood case, with the aim of protecting the interests of hemophilia patients,” Farzadifar added.
She called on the government to cooperate in this matter, highlighting the tragic case of the first hemophilia patient with Factor VIII – a seven-year-old child who became the first victim of AIDS.
The case centers around a French institute that exported HIV-infected products to several countries, including Italy, Argentina, Saudi Arabia, Iraq, and Iran in 1984 and 1985. This led to the death of numerous hemophilic and thalassemic patients.